No Data
No Data
Looking Into Matinas BioPharma Hldgs's Recent Short Interest
Matinas BioPharma Hldgs's (NYSE:MTNB) short percent of float has risen 6.98% since its last report. The company recently reported that it has 2.24 million shares sold short, which is 0.92% of all
Maxim Group Maintains Matinas BioPharma(MTNB.US) With Buy Rating, Maintains Target Price $1
Maxim Group analyst Jason McCarthy maintains $Matinas BioPharma(MTNB.US)$ with a buy rating, and maintains the target price at $1.According to TipRanks data, the analyst has a success rate of 26.5% an
Express News | Matinas BioPharma Reports Successful Treatment of Patient With Limb-Threatening Mucor Infection in Its Oral Mat2203 Compassionate/Expanded Use Access Program
Matinas BioPharma's Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. With Antifungal Expert Dr. David S. Perlin
BEDMINSTER, N.J., June 13, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersAnitra (AMEX:AZTR) shares increased by 6.5% to $0.18 during Wednesday's after-market session. The market value of their outstanding shares is at $5.1 million. Oragenics (AMEX:OGEN) shares incre
Express News | Matinas BioPharma Says New In Vitro Data Showing LNC Platform Delivering Small Oligonucleotides Presented At TIDES USA 2024
No Data
104681729 :![rocket 🚀](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f680.png)
![rocket 🚀](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f680.png)
![rocket 🚀](https://static.moomoo.com/nnq/emoji/static/image/img-apple-64/1f680.png)